Lemelson Capital Management

Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings
Lemelson Capital Demands Geospace Replace Leadership, Explore Company Sale
Ligand Down 20% Since August 1; What's The Street Thinking?
Lemelson Capital Demands Geospace Replace Leadership, Explore Company Sale
Ligand Down 20% Since August 1; What's The Street Thinking?
EXCLUSIVE: Why Lemelson Is Still Short Netflix
Tilson Covers Short Position In Lumber Liquidators; Hedge Fund Manager Says Company 'Isn't Evil'

Lemelson Capital Management Recent News

Hedge Fund Manager: Why Would Anyone Sell Apple?
Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma
Exclusive: Why This Hedge Fund Manager Is Short Netflix
This Mega-Hedge Fund Manager Is Short Sketchers
This Hedge Fund Manager 'Wouldn't Be Surprised' If iPhone Units Hit 60 Million
Hedge Fund Manager Questions WWE's Partnership With DraftKings
This Hedge Fund Manager Spoke With Lumber Liquidators' Chairman -- Here's What He Thinks
This Hedge Fund Manager Is 'Increasingly Confident In The Success Of Apple Watch'
Tilson's Lumber Liquidators Story Doesn't Add Up, Lemelson Capital CIO Says
WWE Rises On Earnings Beat, But Are Investors Missing Something?
Hedge Fund Manager Says Ackman Shorting Whole Foods 'Doesn't Seem Likely'
This Hedge Fund Manager Says 'Stay Away' From Alibaba
Mega-Hedge Fund Manager: Facebook's Stock Price 'Hardly Represents Any Sort Of Value'
Hedge Fund Manager On WWE: Giving The Service Away For Free Probably Won't Help Earnings
Hedge Fund Manager Expects 70-75 Million Apple iPhones Sold In FQ1
Why This Hedge Fund Manager Thinks Apple Watch Doesn't Need To Succeed In 2015
Hedge Fund Manager On Herbalife: 'Bill Ackman Has Been Right All Along'
Why This Hedge Fund Manager Sees Apple At $150
Hedge Fund Guru Emmanuel Lemelson Explains How To Balance Investments And Morality In Ferguson, MO
Why WWE Network Subscriptions Might Not Be A Big Deal
Lemelson Capital Management Announces Stake In Geospace Technologies
Why Lemelson Capital Is Short On Ligand Pharmaceuticals
Shares Of Ligand Follow Parabolic Curve Amid Responses Surrounding Promacta's Phase III Trial